Literature DB >> 10425084

(R)-3,3,3-Trifluoro-2-hydroxy-2-methylpropionamides are orally active inhibitors of pyruvate dehydrogenase kinase.

T D Aicher1, R C Anderson, G R Bebernitz, G M Coppola, C F Jewell, D C Knorr, C Liu, D M Sperbeck, L J Brand, R J Strohschein, J Gao, C C Vinluan, S S Shetty, C Dragland, E L Kaplan, D DelGrande, A Islam, X Liu, R J Lozito, W M Maniara, R E Walter, W R Mann.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10425084     DOI: 10.1021/jm9902584

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  4 in total

Review 1.  Anticancer agents that counteract tumor glycolysis.

Authors:  Carlotta Granchi; Filippo Minutolo
Journal:  ChemMedChem       Date:  2012-06-08       Impact factor: 3.466

2.  Pyruvate dehydrogenase kinase-4 structures reveal a metastable open conformation fostering robust core-free basal activity.

Authors:  R Max Wynn; Masato Kato; Jacinta L Chuang; Shih-Chia Tso; Jun Li; David T Chuang
Journal:  J Biol Chem       Date:  2008-07-24       Impact factor: 5.157

Review 3.  Targeting Tumor Metabolism for Cancer Treatment: Is Pyruvate Dehydrogenase Kinases (PDKs) a Viable Anticancer Target?

Authors:  Wen Zhang; Shao-Lin Zhang; Xiaohui Hu; Kin Yip Tam
Journal:  Int J Biol Sci       Date:  2015-11-01       Impact factor: 6.580

4.  Copper-catalyzed asymmetric methylation of fluoroalkylated pyruvates with dimethylzinc.

Authors:  Kohsuke Aikawa; Kohei Yabuuchi; Kota Torii; Koichi Mikami
Journal:  Beilstein J Org Chem       Date:  2018-03-07       Impact factor: 2.883

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.